Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis C

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 220 articles:
HTML format



Single Articles


    March 2024
  1. NAVEED A, Khalid A, Janjua N, Cloherty GA, et al
    Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population.
    J Viral Hepat. 2024 Mar 14. doi: 10.1111/jvh.13937.
    PubMed     Abstract available


  2. DOBROWOLSKA K, Pawlowska M, Zarebska-Michaluk D, Rzymski P, et al
    Direct-acting antivirals in women of reproductive age infected with hepatitis C virus.
    J Viral Hepat. 2024 Mar 14. doi: 10.1111/jvh.13936.
    PubMed     Abstract available


  3. HAVENS JR, Lofwall MR, Young AM, Staton M, et al
    Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community.
    J Viral Hepat. 2024 Mar 4. doi: 10.1111/jvh.13933.
    PubMed     Abstract available


  4. SULKOWSKI MS, Martinez A, Tyson GL, Scholz K, et al
    Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs.
    J Viral Hepat. 2024 Mar 3. doi: 10.1111/jvh.13927.
    PubMed     Abstract available


    February 2024
  5. WOLFSON-STOFKO B, Hirode G, Vanderhoff A, Karkada J, et al
    Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
    J Viral Hepat. 2024 Feb 22. doi: 10.1111/jvh.13931.
    PubMed     Abstract available


  6. FRYE K, Davis A, Darby R, McDaniel K, et al
    A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety-net hospital.
    J Viral Hepat. 2024 Feb 18. doi: 10.1111/jvh.13913.
    PubMed     Abstract available


  7. WALTER LA, Prados M, Lloyd A, Sontheimer S, et al
    Birth cohort-specific consideration in an Emergency Department Hepatitis C Testing Programme: A description of age-related characteristics and outcomes.
    J Viral Hepat. 2024 Feb 17. doi: 10.1111/jvh.13930.
    PubMed     Abstract available


  8. TULLY DC, Power KA, Sarette J, Stopka TJ, et al
    Validation of dried blood spots for capturing hepatitis C virus diversity for genomic surveillance.
    J Viral Hepat. 2024 Feb 16. doi: 10.1111/jvh.13924.
    PubMed     Abstract available


  9. EPSTEIN RL, Buzzee B, White LF, Feld JJ, et al
    Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus.
    J Viral Hepat. 2024 Feb 7. doi: 10.1111/jvh.13925.
    PubMed     Abstract available


  10. LV R, Lu Y, Xiang W, Meng M, et al
    Chronic viral hepatitis C micro-elimination program using telemedicine in Guigang city.
    J Viral Hepat. 2024 Feb 7. doi: 10.1111/jvh.13922.
    PubMed     Abstract available


    January 2024
  11. POLLOCK TS, Robert CA, Seybold DJ, Hur M, et al
    Prevalence of hepatitis C among pregnant women in an Appalachian population.
    J Viral Hepat. 2024 Jan 18. doi: 10.1111/jvh.13911.
    PubMed     Abstract available


  12. HIBBERT M, Simmons R, Sabin CA, Mandal S, et al
    Identifying missed opportunities for hepatitis C virus antenatal testing and diagnosis in England.
    J Viral Hepat. 2024 Jan 4. doi: 10.1111/jvh.13906.
    PubMed     Abstract available


  13. QURESHI H, Duran AC, Mahmood H, Sarwar Z, et al
    Context-dependent accuracy of the cobas plasma separation card for HCV RNA viral load measurement.
    J Viral Hepat. 2024 Jan 2. doi: 10.1111/jvh.13910.
    PubMed     Abstract available


    December 2023
  14. O'KEEFE D, Jacka D, Douglass C, Gunn J, et al
    Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines: Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia.
    J Viral Hepat. 2023 Dec 29. doi: 10.1111/jvh.13909.
    PubMed     Abstract available


  15. ALQAHTANI SA, Stepanova M, Al Shabeeb R, Eberly KL, et al
    The impact of hepatitis B and C positive serologies on the outcomes of non-hepatic solid organ transplantation in the United States.
    J Viral Hepat. 2023 Dec 29. doi: 10.1111/jvh.13916.
    PubMed     Abstract available


  16. TOYODA H, Koshiyama Y, Yasuda S, Kumada T, et al
    Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection.
    J Viral Hepat. 2023 Dec 26. doi: 10.1111/jvh.13907.
    PubMed     Abstract available


  17. ZHOU S, Qi K, Bersoff-Matcha SJ, Mishra P, et al
    Sex-related difference analyses of efficacy and safety in clinical trials of direct-acting antivirals to treat chronic HCV genotype 1 and 3 infections.
    J Viral Hepat. 2023 Dec 19. doi: 10.1111/jvh.13901.
    PubMed     Abstract available


  18. RAZAVI H, Blach S, Bregenzer A, Bruggmann P, et al
    Assessing the hepatitis C epidemiology in Switzerland: It is not that trivial.
    J Viral Hepat. 2023 Dec 8. doi: 10.1111/jvh.13904.
    PubMed    


    November 2023
  19. O'SULLIVAN M, Jones AM, Mourad A, Haddadin Y, et al
    Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated-Test-stage Treat study final outcomes.
    J Viral Hepat. 2023 Nov 28. doi: 10.1111/jvh.13897.
    PubMed     Abstract available


  20. HAJARIZADEH B, Carson JM, Byrne M, Grebely J, et al
    Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
    J Viral Hepat. 2023 Nov 7. doi: 10.1111/jvh.13895.
    PubMed     Abstract available


  21. TRELOAR C, Rance J, Bryant J, Lafferty L, et al
    "There's too much power in this number. It's freaking the whole response out": the views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia.
    J Viral Hepat. 2023 Nov 2. doi: 10.1111/jvh.13896.
    PubMed     Abstract available


    October 2023
  22. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
    Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
    J Viral Hepat. 2023 Oct 7. doi: 10.1111/jvh.13892.
    PubMed    


    September 2023
  23. EVANS KN, Vettese T, Wortley PM, Gandhi AP, et al
    HIV and HCV testing at clinical encounters among people who inject drugs, 2013-2018-Opportunities for increased testing and prevention.
    J Viral Hepat. 2023 Sep 19. doi: 10.1111/jvh.13877.
    PubMed     Abstract available


  24. CAROLINE A, Kate M, Roberts M, Ryan J, et al
    What is the impact of a Hepatitis C 'test, trace and treat' pilot using peer workers?
    J Viral Hepat. 2023 Sep 18. doi: 10.1111/jvh.13888.
    PubMed     Abstract available


  25. JOHNSON A, Shearer J, Thompson C, Jelley R, et al
    Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
    J Viral Hepat. 2023 Sep 12. doi: 10.1111/jvh.13887.
    PubMed     Abstract available


    August 2023
  26. BLACH S, Bregenzer A, Bruggmann P, Cerny A, et al
    Assessing the hepatitis C epidemiology in Switzerland: it's not that trivial.
    J Viral Hepat. 2023 Aug 8. doi: 10.1111/jvh.13879.
    PubMed    


    July 2023
  27. PERAZZO H, Castro R, Villela-Nogueira C, Torres M, et al
    Acceptability and usability of oral fluid HCV self-testing for hepatitis C diagnosis: A systematic review and meta-analysis.
    J Viral Hepat. 2023 Jul 23. doi: 10.1111/jvh.13876.
    PubMed     Abstract available


  28. TORRES C, Bauer G, Aubriet S, Scholtes C, et al
    Profile of patients with a positive HCV viral load in a large French psychiatric hospital (2019-2021): A case-control study.
    J Viral Hepat. 2023 Jul 23. doi: 10.1111/jvh.13875.
    PubMed     Abstract available


  29. ROSSOTTI R
    Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply.
    J Viral Hepat. 2023 Jul 11. doi: 10.1111/jvh.13871.
    PubMed    


  30. LU M, Salgia R, Li J, Trudeau S, et al
    Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C.
    J Viral Hepat. 2023 Jul 6. doi: 10.1111/jvh.13859.
    PubMed     Abstract available


    June 2023
  31. COYLE CR, Desjardins MR, Curriero FC, Rudolph J, et al
    Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD.
    J Viral Hepat. 2023 Jun 29. doi: 10.1111/jvh.13864.
    PubMed     Abstract available


  32. GORDON SC, Kaushik A, Chastek B, Anderson A, et al
    Characteristics associated with receipt of treatment among patients diagnosed with chronic hepatitis C virus.
    J Viral Hepat. 2023 Jun 28. doi: 10.1111/jvh.13860.
    PubMed     Abstract available


  33. BARRE T, Zucman D, Marcellin F, Ramier C, et al
    Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2023 Jun 26. doi: 10.1111/jvh.13865.
    PubMed    


  34. TRICKEY A, Ingle SM, Boyd A, Gill MJ, et al
    Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.
    J Viral Hepat. 2023 Jun 20. doi: 10.1111/jvh.13863.
    PubMed     Abstract available


  35. HOVAGUIMIAN F, Beeler PE, Mullhaupt B, Gunthard HF, et al
    Mortality and morbidity related to hepatitis C virus infection in hospitalized adults-A propensity score matched analysis.
    J Viral Hepat. 2023 Jun 12. doi: 10.1111/jvh.13861.
    PubMed     Abstract available


  36. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
    Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
    J Viral Hepat. 2023 Jun 6. doi: 10.1111/jvh.13842.
    PubMed     Abstract available


  37. DE A, Charak S, Bhagat N, Rathi S, et al
    Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
    J Viral Hepat. 2023 Jun 1. doi: 10.1111/jvh.13844.
    PubMed     Abstract available


    May 2023
  38. JACOBSON IM, Bourgeois S, Mathurin P, Thuluvath P, et al
    The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
    J Viral Hepat. 2023;30:448-454.
    PubMed     Abstract available


    April 2023
  39. PASSOS-CASTILHO AM, Murphy DG, Blouin K, Benedetti A, et al
    A population-based study of reported hepatitis C diagnoses from 1998 to 2018 in immigrants and nonimmigrants in Quebec, Canada.
    J Viral Hepat. 2023 Apr 18. doi: 10.1111/jvh.13837.
    PubMed     Abstract available


    March 2023
  40. HIBBERT M, Simmons R, Harris H, Desai M, et al
    Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
    J Viral Hepat. 2023 Mar 17. doi: 10.1111/jvh.13835.
    PubMed     Abstract available


  41. MOREAU C, Roux M, Riou J, Canivet CM, et al
    Dynamic Personalized Prediction of the Individual Liver-Related Risk after Sustained Viral Response in HCV patients.
    J Viral Hepat. 2023 Mar 9. doi: 10.1111/jvh.13830.
    PubMed     Abstract available


  42. QIU L, Xu S, Qiu Y, Liu Y, et al
    Comparison of acknowledged hepatocellular carcinoma risk scores in high risk hepatitis C patients with sustained virologic response.
    J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13829.
    PubMed     Abstract available


  43. MOONEYHAN E, De la Torre Rosas A, Serrano DB, Gamkrelidze I, et al
    Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico.
    J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13828.
    PubMed     Abstract available


  44. SELIM R, Zhou Y, Gordon SC, Zhang T, et al
    Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals.
    J Viral Hepat. 2023 Mar 5. doi: 10.1111/jvh.13826.
    PubMed     Abstract available


    February 2023
  45. SHAH SHBU, Alavi M, Hajarizadeh B, Matthews G, et al
    Liver-related mortality among people with hepatitis B and C: evaluation of definitions based on linked healthcare administrative datasets.
    J Viral Hepat. 2023 Feb 27. doi: 10.1111/jvh.13824.
    PubMed     Abstract available


  46. ZHOU Y, Zhao B, Shi W, Ding X, et al
    The infection rates of HBV and HCV decreased significantly in Zhejiang Province, China: a comparative study based on the data of two sero-epidemiological surveys in 1992 and 2020.
    J Viral Hepat. 2023 Feb 20. doi: 10.1111/jvh.13820.
    PubMed     Abstract available


  47. ROSSOTTI R, Merli M, Baiguera C, Bana NB, et al
    Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals.
    J Viral Hepat. 2023 Feb 11. doi: 10.1111/jvh.13818.
    PubMed     Abstract available


    January 2023
  48. TERRAULT NA, Slepin J, Kanner R, Gailloux K, et al
    Strategies to Increase Primary Care Provider Capacity for Hepatitis C Care: The California ECHO-PLUS Study.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13807.
    PubMed     Abstract available


  49. HUDSON-BUHAGIAR J, Carson J, Monaghan S, Collie P, et al
    Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: a national real-world cohort (REACH-C).
    J Viral Hepat. 2023 Jan 18. doi: 10.1111/jvh.13803.
    PubMed     Abstract available


  50. MOONEYHAN E, Qureshi H, Mahmood H, Tariq M, et al
    Hepatitis C prevalence and elimination planning in Pakistan, a bottom-up approach accounting for provincial variation.
    J Viral Hepat. 2023 Jan 17. doi: 10.1111/jvh.13802.
    PubMed     Abstract available


  51. MCKEEVER A, O'Donovan D, Kee F
    Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community - a Summary Scoping Review.
    J Viral Hepat. 2023 Jan 12. doi: 10.1111/jvh.13801.
    PubMed     Abstract available


  52. DEBETTE-GRATIEN M, Francois S, Chevalier C, Alain S, et al
    Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days.
    J Viral Hepat. 2023 Jan 3. doi: 10.1111/jvh.13798.
    PubMed     Abstract available


    December 2022
  53. KOZUKA R, Tamori A, Enomoto M, Muto-Yukawa Y, et al
    Risk Factors for Liver-Related and Non-Liver-Related Mortality following a Sustained Virological Response after Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in a Real-World Cohort.
    J Viral Hepat. 2022 Dec 30. doi: 10.1111/jvh.13795.
    PubMed     Abstract available


  54. UCHIDA T, Yuji T, Imamura M, Abe-Chayama H, et al
    A novel cDNA-uPA/SCID/Rag2(-/-) /Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system.
    J Viral Hepat. 2022 Dec 27. doi: 10.1111/jvh.13793.
    PubMed     Abstract available


  55. YOUSAFZAI MT, Alavi M, Valerio H, Hajarizadeh B, et al
    Hepatitis C care cascade before and during the direct acting antiviral eras in New South Wales, Australia: a population-based linkage study.
    J Viral Hepat. 2022 Dec 19. doi: 10.1111/jvh.13791.
    PubMed     Abstract available


  56. SIEGELE-BROWN C, Siegele-Brown M, Cook C, Khakoo SI, et al
    Testing to sustain Hepatitis C elimination targets in people who inject drugs: a network-based model.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13786.
    PubMed     Abstract available


  57. LAM L, Fontaine H, Lapidus N, Bellet J, et al
    Performance of Algorithms for Identifying Patients With Chronic Hepatitis B or C Infection in the French Health Insurance Claims Databases Using the ANRS CO22 HEPATHER Cohort.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13788.
    PubMed     Abstract available


  58. SARACCO M, Tandoi F, Maletta F, Balagna R, et al
    Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.
    J Viral Hepat. 2022 Dec 7. doi: 10.1111/jvh.13782.
    PubMed     Abstract available


  59. ROHRIG AM, Jakobi K, Dietz J, Thomas D, et al
    The Role of Serum Sphingolipids as potential biomarkers of non-response to Direct Acting Antiviral-Therapy in Chronic Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Dec 4. doi: 10.1111/jvh.13776.
    PubMed     Abstract available


  60. GREENWALD ZR, Bouck Z, McLean E, Mason K, et al
    Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: a cross-sectional analysis.
    J Viral Hepat. 2022 Dec 3. doi: 10.1111/jvh.13780.
    PubMed     Abstract available


  61. ABDELHAMED W, El-Kassas M
    Hepatocellular Carcinoma and Hepatitis C Virus Treatments: The Bold and The Beautiful.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13778.
    PubMed     Abstract available


  62. FELD JJ, Forns X, Dylla DE, Kumada H, et al
    Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
    J Viral Hepat. 2022;29:1050-1061.
    PubMed     Abstract available


    November 2022
  63. HYDE Z, Roura R, Signer D, Patel A, et al
    Evaluation of a Pilot Emergency Department Linkage to Care Program for Patients Previously Diagnosed with Hepatitis C.
    J Viral Hepat. 2022 Nov 28. doi: 10.1111/jvh.13774.
    PubMed     Abstract available


  64. PERAZZO H, Silva MST, Coutinho C, Peixoto EM, et al
    Monkeypox outbreak as an opportunity to identify new cases of HCV infection in limited resource settings.
    J Viral Hepat. 2022 Nov 10. doi: 10.1111/jvh.13771.
    PubMed    


    October 2022
  65. BITTENCOURT PL, Iasi MDSF, Viana MV, Crespo DM, et al
    Poor linkage to care may compromise the brazilian plan for hepatitis c elimination.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13762.
    PubMed     Abstract available


  66. CASEY JL, Dore GJ, Grebely J, Matthews GV, et al
    Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13761.
    PubMed     Abstract available


  67. CHADHA N, Turner A, Sterling RK
    Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13763.
    PubMed     Abstract available


  68. HEO M, Pericot-Valverde I, Niu J, Norton BL, et al
    More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL Study.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13756.
    PubMed     Abstract available


  69. MENDIZABAL M, Thompson M, Gonzalez-Ballerga E, Anders M, et al
    Implementation of a re-linkage to care strategy in patients with chronic hepatitis C who were lost to follow-up in Latin America.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13758.
    PubMed     Abstract available


  70. BRYCE K, Smith C, Rodger A, Macdonald D, et al
    Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13757.
    PubMed     Abstract available


    September 2022
  71. CAREY I, Christiana M, Marie-Ange M, Teresa B, et al
    Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: universal screening is more comprehensive.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13752.
    PubMed     Abstract available


  72. MCDANIEL K, Utz AE, Akbashev MY, Fuller K, et al
    Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study.
    J Viral Hepat. 2022 Sep 14. doi: 10.1111/jvh.13750.
    PubMed     Abstract available


  73. HARTL L, Jachs M, Bauer D, Simbrunner B, et al
    An HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13746.
    PubMed     Abstract available


  74. REYNOLDS L, Franco R, Prado M, Rodgers JB, et al
    Hepatitis C Active Viremia Over Time in an ED-based Testing Program: Impact, Disparities,.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13744.
    PubMed     Abstract available


  75. YANG AH, Yardeni D, Hercun J, Kleiner DE, et al
    Shear Wave Elastography: How well does it perform in Chronic Hepatitis D Virus Infection?
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13745.
    PubMed     Abstract available


    August 2022
  76. YOUNOSSI ZM, Yu ML, El-Kassas M, Esmat G, et al
    Severe Impairment of Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Seen in Real-World Practices Across the World: Data from the Global Liver Registry.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13741.
    PubMed     Abstract available


  77. MARTIN M, Roth PJ, Niu J, Pericot-Valverde I, et al
    Changes in Alcohol Use during Hepatitis C Treatment in Persons Who Inject Drugs.
    J Viral Hepat. 2022 Aug 23. doi: 10.1111/jvh.13737.
    PubMed     Abstract available


  78. BARRANCO MA, Rosenberg ES, Flanigan C, Shufelt S, et al
    A cross-sectional study of Hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    J Viral Hepat. 2022 Aug 4. doi: 10.1111/jvh.13735.
    PubMed     Abstract available


    July 2022
  79. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Original article Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13728.
    PubMed     Abstract available


  80. FORD JS, Hollywood E, Steuble B, Meng Z, et al
    Risk Factors for Hepatitis C Virus Infection at a Large Urban Emergency Department.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13730.
    PubMed     Abstract available


    June 2022
  81. FACTOR SH, Fierer DS
    Can Treatment, Without Prevention, Eliminate Hepatitis C Among Men Who Have Sex With Men?
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13726.
    PubMed    


  82. TRAEGER MW, van Santen DK, Sacks-Davis R, Asselin J, et al
    Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
    J Viral Hepat. 2022 Jun 20. doi: 10.1111/jvh.13723.
    PubMed     Abstract available


  83. SHIHA G, Soliman R, Mikhail NNH, Carrat F, et al
    International Multicenter Validation of GES score for HCC risk stratification in chronic hepatitis C patients.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13717.
    PubMed     Abstract available


  84. EVON DM, Dong M, Reeve BB, Peter J, et al
    Sustainable and Equivalent Improvements in Symptoms and Functional Well-Being Following Viral Cure from Ledipasvir/Sofosbuvir versus Elbasvir/Grazoprevir for Chronic Hepatitis C Infection: Findings from the randomized PRIORITIZE trial.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13716.
    PubMed     Abstract available


  85. HSU WF, Lai HC, Chuang PH, Su WP, et al
    Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13715.
    PubMed     Abstract available


  86. ROBINS A, Dolman G, Williams S, Gelson W, et al
    Hepatitis E Case Series. A UK Experience.
    J Viral Hepat. 2022 Jun 2. doi: 10.1111/jvh.13714.
    PubMed     Abstract available


    May 2022
  87. ASKAR S, Jelley R, McQue K, Allsop C, et al
    Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13707.
    PubMed     Abstract available


  88. RAMOS-RINCON JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchon C, et al
    Hepatitis C Hospitalizations in Spain and Impact of New Curative Antiviral Therapies.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13708.
    PubMed     Abstract available


  89. MARLEY G, Seto WK, Yan W, Chan P, et al
    What facilitates hepatitis B and hepatitis C testing and the role of stigma among primary care patients in China?
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13711.
    PubMed     Abstract available


  90. PRINSENBERG T, Schinkel J, Zantkuijl P, Davidovich U, et al
    Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13706.
    PubMed     Abstract available


  91. CARSON JM, Hajarizadeh B, Hanson J, O'Beirne J, et al
    Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13705.
    PubMed     Abstract available


  92. ZHENG K, Xia T, Liu N, Xia X, et al
    MicroRNA-206 inhibits HCV proliferation through depressing ACC1 lipid synthesis signaling pathway.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13703.
    PubMed     Abstract available


  93. BEER L, Inglis S, Malaguti A, Byrne C, et al
    Randomised Clinical Trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13701.
    PubMed     Abstract available


  94. VARGAS-ACCARINO E, Martinez-Camprecios J, Dominguez-Hernandez R, Rando-Segura A, et al
    Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19.
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13686.
    PubMed     Abstract available


  95. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Live
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13684.
    PubMed     Abstract available


  96. JONES AT, Briones C, Tran T, Moreno-Walton L, et al
    Closing the hepatitis C treatment gap: United States strategies to improve retention in care.
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13685.
    PubMed     Abstract available


  97. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
    J Viral Hepat. 2022 May 2. doi: 10.1111/jvh.13681.
    PubMed     Abstract available


    March 2022
  98. LEE J, Ahn SB, Yim SY, An J, et al
    Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (>/= 65 years old): A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13679.
    PubMed     Abstract available


  99. TERGAST TL, Blach S, Tacke F, Berg T, et al
    Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13680.
    PubMed     Abstract available


  100. HASSAN A, Agustin HGS, Burke L, Kofron R, et al
    Low Incidence and Prevalence of Hepatitis C in Two Cohorts of HIV Pre-Exposure Prophylaxis Adherence Interventions in Men Who Have Sex with Men in Southern California.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13678.
    PubMed     Abstract available


  101. WARD E, Carlisle N, Williams E, Heath SL, et al
    Prevalence of Hepatitis C in Sexual Assault Survivors Presenting to a SANE Clinic: A Descriptive Analysis.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13675.
    PubMed     Abstract available


  102. OZGA JE, Syvertsen JL, Pollini RA
    Hepatitis C Antibody Prevalence, Correlates, and Barriers to Care among People Who Inject Drugs in Central California.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13677.
    PubMed     Abstract available


  103. NEBBIA G, Ruf M, Hunter L, Balasegaram S, et al
    The VirA+EmiC project - Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13676.
    PubMed     Abstract available


  104. KRINGS A, Schmidt D, Meixenberger K, Bannert N, et al
    Decreasing prevalence and stagnating incidence of Hepatitis C-coinfection among a cohort of HIV-1-positive patients, with a majority of men who have sex with men, in Germany, 1996-2019.
    J Viral Hepat. 2022 Mar 18. doi: 10.1111/jvh.13670.
    PubMed     Abstract available


  105. MORGAN JR, Marsh E, Savinkina A, Shilton S, et al
    Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset.
    J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672.
    PubMed     Abstract available


  106. VERACRUZ N, Gish RG, Cheung R, Chitnis AS, et al
    Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13663.
    PubMed     Abstract available


  107. HOWELL J, Traeger MW, Williams B, Layton C, et al
    The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664.
    PubMed     Abstract available


  108. CHROMY D, Bauer DJM, Simbrunner B, Jachs M, et al
    'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13665.
    PubMed     Abstract available


  109. AKIYAMA MJ, Riback L, Nyakowa M, Musyoki H, et al
    Hepatitis C Treatment Outcomes Among People Who Inject Drugs Accessing Harm Reduction Settings in Kenya.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13662.
    PubMed     Abstract available


  110. KAUR H, Dhiman RK, Kulkarni AV, Premkumar M, et al
    Improvement of Chronic HCV infection related Depression, Anxiety, and Neurocognitive performance in persons achieving SVR-12: a Real-world Cohort Study.
    J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13668.
    PubMed     Abstract available


  111. NEPHEW LD, Wang Y, Mohamed K, Nichols D, et al
    Removal of Medicaid Restrictions were Associated with Increased Hepatitis-C Virus Treatment Rates, But Disparities Persist.
    J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661.
    PubMed     Abstract available


    February 2022
  112. HOSSEINI-HOOSHYAR S, Alavi M, Martinello M, Valerio H, et al
    Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.
    J Viral Hepat. 2022 Feb 17. doi: 10.1111/jvh.13658.
    PubMed     Abstract available


  113. WU G, Zhou A, Kwon S
    Integrating Hepatitis C Virus Screening of Baby Boomers at a Community Hospital Emergency Department.
    J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13654.
    PubMed     Abstract available


  114. KHERA T, Madsen LW, Du Y, Lillevang ST, et al
    Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.
    J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13652.
    PubMed     Abstract available


    January 2022
  115. HUA R, Kong F, Wen X, Xiong Q, et al
    Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection - an open-label, phase 2 study.
    J Viral Hepat. 2022 Jan 26. doi: 10.1111/jvh.13650.
    PubMed     Abstract available


  116. WU S, Yuan H, Fan H, Xu Y, et al
    Evolutionary characteristics and immune mutation of hepatitis C virus genotype 1b among intravenous drug users in mainland, China.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13647.
    PubMed     Abstract available


  117. STOCKDALE AJ, Kreuels B, Shawa IT, Meiring JE, et al
    A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13646.
    PubMed     Abstract available


  118. IKENAGA H, Uchida-Kobayashi S, Tamori A, Odagiri N, et al
    Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.
    J Viral Hepat. 2022;29:52-59.
    PubMed     Abstract available


    December 2021
  119. DJORDJEVIC F, Ryan K, Gunn J, Brener L, et al
    Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia.
    J Viral Hepat. 2021;28:1738-1743.
    PubMed     Abstract available


    November 2021
  120. GIADANS CG, Rios DA, Ameigeiras B, Haddad L, et al
    Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13635.
    PubMed     Abstract available


  121. MANDEL E, Peci A, Cronin K, Capraru CI, et al
    The Impact of the First, Second, and Third Waves of COVID-19 on Hepatitis B and C Testing in Ontario, Canada.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13637.
    PubMed     Abstract available


  122. FORNS X, Colom J, Garcia-Retortillo M, Quer JC, et al
    Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination.
    J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13634.
    PubMed     Abstract available


  123. MOHAMED EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, et al
    Electronic Nose versus Quadrupole Mass Spectrometry for Identifying Viral Hepatitis C Patients.
    J Viral Hepat. 2021 Nov 12. doi: 10.1111/jvh.13630.
    PubMed     Abstract available


  124. CHIDWICK K, Myton R, Rodgers A, Jun M, et al
    A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial).
    J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13629.
    PubMed     Abstract available


  125. GANE E, de Ledinghen V, Dylla DE, Rizzardini G, et al
    Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
    J Viral Hepat. 2021;28:1635-1642.
    PubMed     Abstract available


    October 2021
  126. JUGNARAIN DV, Halford R, Smith S, Hickman M, et al
    Role of peer support in a hepatitis C elimination program.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13626.
    PubMed     Abstract available


  127. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Serum alpha-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13625.
    PubMed     Abstract available


    September 2021
  128. NISHIGUCHI J, McNamara A, Surlyn CS, Eagen KV, et al
    Efficacy of an eConsult Service to Cure Hepatitis C in Primary Care.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13616.
    PubMed     Abstract available


  129. COPPOLA C, Masarone M, Bartoli M, Staiano L, et al
    Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13623.
    PubMed     Abstract available


  130. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Letter in response: Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13619.
    PubMed     Abstract available


  131. RODER C, Nguyen P, Harvey C, Wardrop M, et al
    Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13622.
    PubMed     Abstract available


  132. ROSATO V, Ascione A, Nevola R, Fracanzani AL, et al
    Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617.
    PubMed     Abstract available


  133. CAVEN M, Baiano CX, Robinson EM, Stephens B, et al
    Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    J Viral Hepat. 2021 Sep 15. doi: 10.1111/jvh.13614.
    PubMed     Abstract available


  134. MARCELLIN F, Di Beo V, Esterle L, Abgrall S, et al
    Post-HCV cure self-reported changes in physical activity, eating behaviors, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2021 Sep 2. doi: 10.1111/jvh.13605.
    PubMed     Abstract available


  135. GARCIA-CEHIC D, Rando A, Rodriguez-Frias F, Gregori J, et al
    Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    J Viral Hepat. 2021;28:1319-1324.
    PubMed     Abstract available


    August 2021
  136. PALMER AY, Chan K, Gold J, Layton C, et al
    A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13596.
    PubMed     Abstract available


  137. WONG RJ, Cheung R, Gish RG, Chitnis AS, et al
    Prevalence of Hepatitis E Infection among Adults with Concurrent Chronic Liver Disease.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13597.
    PubMed     Abstract available


  138. BALL LE, Agana B, Comte-Walters S, Rockey DC, et al
    Hepatitis C Virus Treatment with Direct Acting Antivirals Induces Rapid Changes in the Hepatic Proteome.
    J Viral Hepat. 2021 Aug 11. doi: 10.1111/jvh.13593.
    PubMed     Abstract available


  139. KNOP V, Hoppe D, Vermehren J, Troetschler S, et al
    Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 year follow-up of a prospective longitudinal study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13587.
    PubMed     Abstract available


  140. HUPPE D, Stoehr A, Buggisch P, Mauss S, et al
    The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 Aug 2. doi: 10.1111/jvh.13586.
    PubMed     Abstract available


    July 2021
  141. SANTOS-LIMA C, Souza-Marques B, Vieira F, Schinoni MI, et al
    Neuropsychological effects of direct-acting antiviral treatment for HCV subjects: a systematic review.
    J Viral Hepat. 2021 Jul 28. doi: 10.1111/jvh.13584.
    PubMed     Abstract available


  142. WANG Y, Zhao Z, Zhang H, Lin Q, et al
    Estimating the transmissibility of hepatitis C: a modelling study in Yichang City, China.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13582.
    PubMed     Abstract available


  143. DEL ROSARIO A, Eldredge JD, Doorley S, Mishra SI, et al
    Hepatitis C Virus Care Cascade in Persons Experiencing Homelessness in the United States in the Era of Direct-Acting Antiviral Agents: A Scoping Review.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13583.
    PubMed     Abstract available


  144. OHKI T, Satov K, Kondo M, Goto E, et al
    Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13579.
    PubMed     Abstract available


  145. YOUSAFZAI MT, Bajis S, Alavi M, Grebely J, et al
    Treatment cascade of care for chronic hepatitis C virus infection globally: Systematic review and meta-analysis.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13574.
    PubMed     Abstract available


  146. BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
    Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
    J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
    PubMed     Abstract available


  147. BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
    The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
    J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
    PubMed     Abstract available


  148. VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
    A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
    PubMed     Abstract available


  149. ERICE A, Varillas-Delgado D, Caballero C
    Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
    PubMed     Abstract available


  150. MCGUIRE FH, Andre K, Bradsher ML, Harrison D, et al
    Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
    J Viral Hepat. 2021;28:982-993.
    PubMed     Abstract available


    June 2021
  151. KIM HP, Edwards A, Reeve BB, Golin CE, et al
    Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
    PubMed     Abstract available


  152. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
    PubMed     Abstract available


  153. KANG Q, Xu J, Luo H, Tan N, et al
    Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
    PubMed     Abstract available


    May 2021
  154. BROWN C, Siegele M, Wright M, Cook C, et al
    Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
    PubMed     Abstract available


  155. SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
    Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
    PubMed     Abstract available


  156. OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
    Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
    PubMed     Abstract available


  157. LIU PC, Chan C, Huang YH, Chen YJ, et al
    Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
    PubMed     Abstract available


  158. KIM S, Powell J, Naugle J, Ricco M, et al
    Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
    PubMed     Abstract available


  159. MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
    Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
    PubMed     Abstract available


  160. COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
    Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
    PubMed     Abstract available


    April 2021
  161. CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
    Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
    PubMed     Abstract available


  162. FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
    Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
    PubMed     Abstract available


  163. HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
    Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
    PubMed     Abstract available


  164. GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
    Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
    PubMed     Abstract available


  165. LEE TH, Chan A, Bryan W, Park L, et al
    Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
    J Viral Hepat. 2021;28:630-636.
    PubMed     Abstract available


    March 2021
  166. BUTT AA, Yan P
    Natural History of Hepatitis C Virus Infection in a Large National Seroconversion Cohort in the Direct Acting Antiviral Agent Era: Results from ERCHIVES.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13507.
    PubMed     Abstract available


  167. LIU CH, Sun HY, Hsieh SM, Liu WC, et al
    Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct acting antivirals and antiretroviral therapy.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13502.
    PubMed     Abstract available


  168. BAIANO CX, Caven M, Robinson EM, Dillon JF, et al
    Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13505.
    PubMed     Abstract available


  169. MACGREGOR L, Ward Z, Martin NK, Nicholls J, et al
    The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13503.
    PubMed     Abstract available


  170. MACIAS J, Tellez F, de Los Santos I, Morano LE, et al
    Impact of recent drug use on the efficacy of Elbasvir/Grazoprevir for HCV-infected people on opioid agonist therapy.
    J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13496.
    PubMed     Abstract available


  171. JIANG JJ, Shiels MS, O'Brien TR
    Death Certificates Compared to SEER-Medicare Data for Surveillance of Liver Cancer Mortality Due to Hepatitis B or Hepatitis C Infection.
    J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13498.
    PubMed     Abstract available


  172. PERICOT-VALVERDE I, Rennert L, Heo M, Akiyama MJ, et al
    Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
    J Viral Hepat. 2021;28:548-557.
    PubMed     Abstract available


    February 2021
  173. BAR N, Levy S, Deutsch L, Leshno M, et al
    Hepatitis C related cognitive impairment: impact of viral and host factors and response to therapy.
    J Viral Hepat. 2021 Feb 23. doi: 10.1111/jvh.13492.
    PubMed     Abstract available


  174. BANDERA A, Lorenzini P, Taramasso L, Cozzi-Lepri A, et al
    The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: data from the ICONA Foundation Cohort.
    J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13488.
    PubMed     Abstract available


  175. VEGAS JJ, Flores-Herrera J, Latasa P, Garrido-Estepa M, et al
    Reduction in hepatitis C-related hospitalisations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences.
    J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13491.
    PubMed     Abstract available


  176. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
    J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13487.
    PubMed     Abstract available


  177. TOKUCHI Y, Suda G, Kimura M, Maehara O, et al
    Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13484.
    PubMed     Abstract available


  178. FRAZZONI L, Sikandar U, Mazzella G, Fuccio L, et al
    A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13486.
    PubMed     Abstract available


  179. SAHAKYAN Y, Lee-Kim V, Bremner KE, Bielecki JM, et al
    Impact of direct acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C: systematic review and meta-analysis.
    J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13482.
    PubMed     Abstract available


  180. VERGARA M, Miquel M, Vela E, Cleries M, et al
    Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents.
    J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13479.
    PubMed     Abstract available


  181. KREKULOVA L, Honzak R, Riley LW
    Viral hepatitis C pandemic: challenges and threats to its elimination.
    J Viral Hepat. 2021 Feb 6. doi: 10.1111/jvh.13480.
    PubMed     Abstract available


  182. WEI YJ, Hsu PY, Lee JJ, Niu SW, et al
    Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uremic patients receiving hemodialysis in Taiwan- the FORMOSA-LIKE group.
    J Viral Hepat. 2021 Feb 3. doi: 10.1111/jvh.13477.
    PubMed     Abstract available


  183. PRITCHARD H, Hwang JP, Angelidakis G, Yibirin M, et al
    Hepatitis B Virus Reactivation in Cancer Patients Receiving Direct-Acting Antivirals for Hepatitis C Virus Infection.
    J Viral Hepat. 2021 Feb 1. doi: 10.1111/jvh.13478.
    PubMed     Abstract available


    January 2021
  184. LOCKART I, Hajarizadeh B, Alavi M, Davison S, et al
    Title: Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
    J Viral Hepat. 2021 Jan 22. doi: 10.1111/jvh.13475.
    PubMed     Abstract available


  185. WILDER JM, Evon DM, Jean Proeschold-Bell R, Yao J, et al
    Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives.
    J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474.
    PubMed     Abstract available


  186. SU X, Zhao X, Deng JL, Li SN, et al
    Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis.
    J Viral Hepat. 2021 Jan 16. doi: 10.1111/jvh.13469.
    PubMed     Abstract available


  187. CHEN B, Ma ZH, Xu B, Chang H, et al
    Evaluation of seven Rapid Diagnostic Tests for Detection of Hepatitis C Virus Antibodies in China.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13466.
    PubMed     Abstract available


  188. SHUMBUSHO F, Liu AF, Kateera F, Kabahizi J, et al
    Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13467.
    PubMed     Abstract available


  189. FRANCESCA ROMANA P, Francesco S, Massimo S, Antonio Giulio B, et al
    Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care center: results of the Telepass project.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13465.
    PubMed     Abstract available


    December 2020
  190. O'GORMAN P, Strahan O, Ferguson D, Monaghan A, et al
    Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-cirrhotic chronic hepatitis C.
    J Viral Hepat. 2020 Dec 28. doi: 10.1111/jvh.13460.
    PubMed     Abstract available


  191. FABBIANI M, Lombardi A, Colaneri M, Del Poggio P, et al
    High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13454.
    PubMed     Abstract available


  192. GORRIS M, van der Lecq BM, van Erpecum KJ, de Bruijne J, et al
    Treatment for Chronic Hepatitis E Virus Infection: A Systematic Review and Meta-analysis.
    J Viral Hepat. 2020 Dec 10. doi: 10.1111/jvh.13456.
    PubMed     Abstract available


  193. CHAN K, Elsum I, Gold J, Layton C, et al
    Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
    J Viral Hepat. 2020 Dec 1. doi: 10.1111/jvh.13447.
    PubMed     Abstract available


    November 2020
  194. TADA T, Toyoda H, Kumada T, Kurisu A, et al
    Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13444.
    PubMed     Abstract available


  195. WHITELEY D, Speakman E, Elliott L, Davidson K, et al
    Provider-related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis.
    J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13443.
    PubMed     Abstract available


  196. RAZAVI H
    The cost effectiveness of hepatitis C virus elimination in low and middle-income countries.
    J Viral Hepat. 2020 Nov 17. doi: 10.1111/jvh.13442.
    PubMed     Abstract available


  197. WEINHEIMER-HAUS EM, Yu X, Singal AG, Naylor KB, et al
    Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan.
    J Viral Hepat. 2020 Nov 13. doi: 10.1111/jvh.13438.
    PubMed     Abstract available


  198. KIM D, Alshuwaykh OS, Cholankeril G, Wong RJ, et al
    Trends in Mortality in Hepatitis C Infection and Alcoholic Liver Disease based on Drug Overdose in the United States.
    J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13435.
    PubMed     Abstract available


  199. RIDRUEJO E, Pinero F, Mendizabal M, Silva M, et al
    Direct-Acting Antivirals Treatment Failure in Genotype 2 Hepatitis C chronic Infection.
    J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13433.
    PubMed     Abstract available


  200. KAPADIA SN, Katzman C, Fong C, Eckhardt BJ, et al
    Hepatitis C Testing and Treatment Uptake among Young People who Use Opioids in New York City: A Cross-Sectional Study.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13437.
    PubMed     Abstract available


  201. WU D, Hu S, Chen G, Jiao C, et al
    Association of Hepatitis C Infection and Risk of Kidney Cancer: A Systematic Review and Meta-analysis of Observational Studies.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13434.
    PubMed     Abstract available


  202. SHEU MJ, Liang FW, Lu TH
    Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13436.
    PubMed     Abstract available


    October 2020
  203. GALLACHER J, McPherson S
    Progress towards micro-elimination of hepatitis C in the custodial setting.
    J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13428.
    PubMed    


  204. FAHNOE U, Pedersen MS, Solund C, Ernst A, et al
    Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13430.
    PubMed     Abstract available


  205. GOYAL A, Perelson AS, Kandathil AJ, Quinn J, et al
    HIV influences clustering and intracellular replication of hepatitis C virus.
    J Viral Hepat. 2020 Oct 30. doi: 10.1111/jvh.13429.
    PubMed     Abstract available


  206. IBRAHIM ES, Abdel-Samiee M, Youssef MI, El-Shazly H, et al
    Variceal Recurrence 4 Years post Endoscopic Band Ligation in Hepatitis C Patients who Achieved Sustained Virological Response with Oral Direct Acting Antiviral Therapy.
    J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13426.
    PubMed     Abstract available


  207. REYES-URUENA J, Celly A, Moreno S, Majo X, et al
    Hepatitis C virus: testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016.
    J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13427.
    PubMed     Abstract available


  208. CHAN J, Kim JJ, Barrett BK, Hamadeh A, et al
    Cost-Effectiveness Analysis of Sofosbuvir and Velpatasvir in Chronic Hepatitis C Patients with Decompensated Cirrhosis.
    J Viral Hepat. 2020 Oct 16. doi: 10.1111/jvh.13419.
    PubMed     Abstract available


  209. LAURSEN TL, Villesen IF, Leeming DJ, Karsdal MA, et al
    Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
    J Viral Hepat. 2020 Oct 15. doi: 10.1111/jvh.13416.
    PubMed     Abstract available


  210. MAFIRAKUREVA N, Lim AG, Khalid GG, Aslam K, et al
    Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
    J Viral Hepat. 2020 Oct 14. doi: 10.1111/jvh.13422.
    PubMed     Abstract available


  211. RAFIQUE S, Zahid S, Ali A, Tariq M, et al
    Genome wide methylation profiling of HCV pathogenesis to develop diabetes and diabetic complications.
    J Viral Hepat. 2020 Oct 13. doi: 10.1111/jvh.13417.
    PubMed     Abstract available


  212. POOLA S, Sanaka S, Sewell K, Tillmann HL, et al
    Hepatitis B Surface Antibody Titers and Hepatitis B Reactivation with Direct-Acting Antiviral Therapy for Hepatitis C.
    J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13421.
    PubMed     Abstract available


    September 2020
  213. MARTINEZ SANZ J, Vivancos MJ, Sanchez-Conde M, Gomez-Ayerbe C, et al
    Hepatitis C and HIV combined screening in primary care: a cluster randomized trial.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13413.
    PubMed     Abstract available


  214. JOHNSON PJ, Berhane S, Walker AJ, Gordon FH, et al
    Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408.
    PubMed     Abstract available


    June 2020
  215. HWA YOUNG C, Mai Thi H, Kim KA, Cho H, et al
    Association between viral hepatitis infection and Parkinson's disease: A population-based prospective study.
    J Viral Hepat. 2020 Jun 17. doi: 10.1111/jvh.13346.
    PubMed     Abstract available


    April 2020
  216. HONG CY, Sinn DH, Kang D, Paik SW, et al
    Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: Anationwide cohort study.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13304.
    PubMed     Abstract available


  217. TSENG CW, Wu SF, Chen CY, Ho YC, et al
    Characteristics of Regulatory T Cell Function in Patients with Chronic Hepatitis B and C Coinfection.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13298.
    PubMed     Abstract available


    March 2020
  218. DARVISHIAN M, Wong S, Binka M, Yu A, et al
    Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    J Viral Hepat. 2020;27:243-260.
    PubMed     Abstract available


    September 2019
  219. VAN SANTEN DK, Boyd A, Bruisten S, Sonder GJ, et al
    Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13205.
    PubMed     Abstract available


    July 2019
  220. MARRONE A, Ciotti M, Rinaldi L, Adinolfi LE, et al
    Hepatitis B and C virus infection and risk of hematological malignancies.
    J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13183.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.